Reduced intensity regimen prior to marrow transplant better for older leukemia patients

December 09, 2012

COLUMBUS, Ohio - A new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) shows that preparing older acute myeloid leukemia (AML) patients for bone marrow transplants with a reduced intensity conditioning regimen appears to be associated with higher rates of disease-free survival relative to the more typical treatments usually given to such patients. The study was presented at the 2012 American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

Typically, the prognosis for older AML patients is poor. Even in patients who achieve complete remission through chemotherapy, survival rates remain low due to high risk of relapse. While blood or bone marrow transplants can be a viable option for younger patients, conventional preparative regimens leading up to the procedure are often too toxic for patients over the age of 60.

"With a reduced intensity regimen leading up to a transplant, the disease free survival rate in older patients reached 39 percent," said Steven M. Devine, MD, Professor of Internal Medicine in the Division of Hematology at The Ohio State University Comprehensive Cancer Center, and director of the Blood and Marrow Transplant Program. "These outcomes are better than those achieved using more conventional treatments and warrant additional comparison research and studies focused on preventing relapse in this patient population."

Methodology & Results

The objective of the Phase II, prospective, multi-center trial was to determine the feasibility and effectiveness of a uniform reduced intensity conditioning regimen prior to a blood cell transplant in older AML patients in clinical remission. The primary endpoint of the study was two-year disease-free survival. Researchers hypothesized that disease-free survival at two years would exceed 20 percent. One hundred twenty three AML patients in first clinical remission following chemotherapy, ages 60-74, were transplanted at 21 centers across the country. Forty seven percent of patients had match related donors and 53 percent had unrelated donors. All but eight patients (who received fludarabine and busulfan alone) were conditioned with the same regimen containing fludarabine (30mg/m2/day x 5), busulfan (6.4mg/kg IV total dose) and antithymocyte globulin (7.5mg/kg total dose). One case of primary graft failure was reported. Rates of both acute and chronic graft vs host disease and treatment related mortality were relatively low. There were no unexpected toxicities associated with these transplants.. Relapse was the most common cause of death.
-end-
This research was conducted through the Alliance and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Session DetailsThe Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.

Ohio State University Wexner Medical Center

Related Transplant Articles from Brightsurf:

Survival on heart transplant waiting list
Survival of patients on the heart transplant waiting list was examined in this observational study.

New hope for kidney revival for transplant
Cell therapy delivered directly to the kidney can revive a 'marginal' organ, improving function and could offer new hope for providing more kidneys for transplant.

First Swedish transplant of uterus from deceased donor
The Swedish team responsible for uterine transplantation research has, for the first time, transplanted a uterus from a deceased donor.

New research may lead to increased use of available hearts for transplant
A new study provides hope that the number of children dying on the transplantation list while waiting for a new heart could potentially be reduced dramatically.

New research finds signal of decreased early post transplant survival in new heart transplant system
In an analysis of the new heart organ allocation system for transplant patients in the US, researchers have identified a signal of a decrease in heart transplant survival rates.

Researchers standardise test for predicting transplant rejection
Researchers from The Westmead Institute for Medical Research have developed a standardised method of measuring the immune response in islet transplant recipients, helping predict patient outcomes.

Measuring quality of life after pediatric kidney transplant
After receiving a kidney transplant, children may experience worrisome quality-of-life changes that underscore the importance of screening transplant recipients for psychosocial function, according to Children's research presented during the 10th Congress of the International Pediatric Transplant Association.

Kidney transplant patients need even better aftercare!
Kidney transplantation is the best renal replacement therapy available. Although survival and quality of life are significantly better compared to dialysis patients, transplant recipients nevertheless have a significantly higher cardiovascular morbidity and mortality than healthy people.

First birth after robot-assisted uterus transplant
A boy 48 centimeters long, weighing 2900 grams, is the first baby born after the technological shift in the Swedish world-leading research on uterine transplantation.

New clues discovered to lung transplant rejection
Researchers at Washington University School of Medicine in St. Louis have discovered clues to a particularly deadly form of rejection that can follow lung transplantation.

Read More: Transplant News and Transplant Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.